Aspire Biopharma Holdings, Inc. · NASDAQ:ASBP
Aspire Biopharma — Investor Presentation (June 2026)
21 slides from Aspire Biopharma's investor presentation, June 2026
Slide 1: Investor Presentation
June 2026 Investor Presentation Nasdaq: ASBP
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by t
Slide 3: Aspire at a Glance
Aspire at a Glance Patent-pending drug delivery technology for rapid sublingual absorption and entry into the bloodstream of drugs and supplements ▪ Enhances the pharmacokinetic performance of Active Pharmaceutical Ingredients (“APIs”), supplements and nutraceuticals into the bloodstream, increasing
Slide 4: Drug and Supplement Delivery Technology Innovator
Drug and Supplement Delivery Technology Innovator Aspire Biopharma has developed Technology delivers fast acting New mechanism of delivery disruptive technologies for drug formulations using our allows rapid sublingual delivering drugs and other absorption into the products sublingually(1). patent-p
Slide 5: Drug and Supplement Delivery Technology Innovator
Drug and Supplement Delivery Technology Innovator Fast Acting Powder-form medication developed using our patent-pending technology enters the bloodstream in a fraction of the time as compared to oral tablets and capsules Easy to Use Dissolves easily under the tongue Dosage Management Drugs avoid fir
Slide 6: Aspire’s Mechanisms of Action
Aspire’s Mechanisms of Action Mouth to Blood Stream Pathways Nature Provides the Mouth with Direct Access to Blood Stream Dorsalis Lingual Artery Lingual Vein Aspire’s sublingual delivery system avoids the Veins of Dorsum of Tongue side effect drugs delivered in pills or tables orally ▪ Avoid damage
Slide 7: Aspire Pipeline, Commercial Opportunities & Planned 2026-27 Milestones
Aspire Pipeline, Commercial Opportunities & Planned 2026-27 Milestones Aspirin Drug Candidate Non-Aspirin Drug Candidates High Dose ▪ Alprazolam (Generic Xanax®): Formulation for sublingual administration of drug for treatment of ✓ Completed clinical trial to evaluate the pharmacodynamic effect of a
Slide 8: Aspire Patent Portfolio
Aspire Patent Portfolio Sublingual Aspirin Product Candidate • Filed provisional patent applications with the USPTO on March 31, 2023 and October 2, 2024, respectively, pertaining to Oral Mucosal Formulations of Aspirin that utilize Aspire’s fast acting formulation. Omnibus Patent Filing • Filed an
Slide 9: Global Market Opportunity for Target Product Portfolio
Global Market Opportunity for Target Product Portfolio Aspire believes its disruptive technology can be applied to a number of approved drugs and supplements Global Analgesics Market Valued at $47.32B in 2023 and projected to reach $75.73B by 2032, growing at a compound annual growth rate (CAGR) of
Slide 10: Sublingual Aspirin Product: Background
Sublingual Aspirin Product: Background Oral aspirin (ASA) with its anti-inflammatory properties has been used world-wide for over 100 years Aspirin is one of the most-studied and understood drugs and universally approved for use. In the past Aspirin-induced GI bleeding has limited the long-term oral
Slide 11: Sublingual Aspirin Product: Clinical Trial
Sublingual Aspirin Product: Clinical Trial Strategy Aspire uses existing, approved generic-drug dosages. Generic drugs do not need to repeat the clinical trials related to active ingredients but must demonstrate sublingual route of administration as it pertains to: • effectiveness • amount of drug t
Slide 12: Sublingual Aspirin Product: Overview and Top-Line Clinical Results
Sublingual Aspirin Product: Overview and Top-Line Clinical Results Study Design and Top-Line Results Plasma ASA Concentrations (ng/mL) over 30 Minutes after ▪ Primary objective of the clinical trial was to evaluate the bioavailability Dosing of acetylsalicylic acid (ASA, the active antiplatelet form
Slide 13: Sublingual Aspirin Product: Overview and Top-Line Clinical Results Serum TxB2
Sublingual Aspirin Product: Overview and Top-Line Clinical Results Mean Serum TxB2* Concentrations (ng/mL) (lower concentrations mean less platelet aggregation) over 30 Minutes after Dosing OTASA BA2038 (Aspire Additional Important Clinical Trial Findings sublingual aspirin granules), OTASA BA002039
Slide 14: Supplement Product BUZZ BOMB Caffeine
Supplement Product BUZZ BOMB Caffeine Global functional foods market size was estimated at $329.65B in 2023 and is projected to reach $586.06B by 2030, growing at a CAGR of 8.6% from 2024 to 2030 • Single serving 50mg caffeine product delivered in a single-serving stick pack of dry powder sprinkled
Slide 15: BUZZ BOMB Disruptive Characteristics
BUZZ BOMB Disruptive Characteristics BUZZ BOMB Caffeine Benefits: • Speed: works nearly immediately (less than 2 minutes) vs. 20-30 minutes • Convenience: small, easy to use single-use packets (no mixing and measuring for beverages) • Energy management: use as needed to precisely manage caffeine int
Slide 16: Functional Foods Market
Functional Foods Market Global functional foods market size was estimated at $329.65B in 2023 and is projected to reach $586.06B by 2030, growing at a CAGR of 8.6% from 2024 to 2030 driven by: ❖ Precision and performance nutrition ❖ Active lifestyle and wellness trends ❖ Rising fitness culture and g
Slide 17: Aspire Business Diversification Strategy
Aspire Business Diversification Strategy 17
Slide 18: Aspire to Acquire Dura Driver Control Systems
Aspire to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue The proposed acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise • D
Slide 19: Dura Control Systems: Operational Pillars and Key Transaction Details
Dura Control: Systems: Operational Pillars and Key Transaction Details Robust Financial Profile: For the fiscal year ended December 31, 2025 (unaudited), DCS generated revenue of more than $200 million, net income of more than $17 million and Adjusted EBITDA of more than $22 million. Adjusted EBITDA
Slide 20: Aspire’s Investment Considerations
Aspire’s Investment Considerations ▪ Multiple ℞ applications in heart attack/stroke, anti-anxiety, antiplatelet, nausea and others ▪ Large addressable ℞ markets for both generic drugs and supplements via commercialization through partnerships, licensing and internal development ▪ High Dose Aspirin P
Slide 21: Thank You.
Aspire BioPharma Holdings, Inc. 23150 Fashion Drive, Suite 232 Thank You. Estero, FL 33928 www.aspirebiolabs.com Investor Relations Kevin McGrath PCG Advisory kevin@pcgadvisory.com Nasdaq: ASBP 21
Aspire Biopharma Holdings — Investor Presentation (June 2026) on 6ix